SuperworthInMed Pharmaceuticals EPS INM
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$3.01
- Latest quarter, Q4 FY26
- −$1.33
- Fiscal year 2026
- −$3.01
InMed Pharmaceuticals' earnings per share was −$3.01 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was −$1.33.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$3.01 | n/a |
| FY2025 | −$9.49 | n/a |
| FY2024 | −$26.56 | n/a |
| FY2023 | −$113.40 | n/a |
| FY2022 | −$647.00 | n/a |
| FY2021 | −$745.00 | n/a |
| FY2020 | −$860.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | −$1.33 | n/a | −$3.01 | |
| Q3 FY26 | −$0.73 | n/a | −$2.88 | |
| Q2 FY26 | −$0.51 | n/a | −$4.09 | |
| Q1 FY26 | −$0.44 | n/a | −$7.22 | |
| Q4 FY25 | −$1.20 | n/a | −$9.49 | |
| Q3 FY25 | −$1.94 | n/a | −$12.32 | |
| Q2 FY25 | −$3.64 | n/a | −$13.96 | |
| Q1 FY25 | −$2.71 | n/a | −$14.03 | |
| Q4 FY24 | −$4.03 | n/a | −$26.56 | |
| Q3 FY24 | −$3.58 | n/a | −$24.53 | |
| Q2 FY24 | −$3.71 | n/a | −$32.95 | |
| Q1 FY24 | −$15.24 | n/a | −$47.44 |
Against its peers
Companies in Drug Manufacturers - General nearest InMed Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INMInMed Pharmaceuticals | −$3.01 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on InMed Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.